Paclitaxel (P) plus carboplatin (C) in advanced non-small cell lung cancer (NSCLC)
Eduardo Richardet(Instituto Oncológico de Córdoba), Lydia Suarez, Miguel Cuevas, N. Pilnik, Marc Abraham, E. Mickiewicz(University of Chicago), O. De Cristófaro, M.A. Callejas, Luis Fein(National Cancer Center), Carlos M. Alasino, Mariacarla Ventriglia(University of Naples Federico II), Federico Cóppola(Hospital Alemán), G. Pascón, S Jovtis, S. Breier, Daniel Lewi, Mariana Trigo, C Delfino(Hospital Privado de Comunidad), G Uranga
Cited by 0
Related Papers
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
|Journal of Clinical Oncology|2007|483
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
|Journal of Clinical Oncology|2000|318